Merck Kgaa Unsp ADR (MKGAY) 38.5300 $MKGAY
Merck KGaA, Darmstadt, Germany to Present Data at ASCO That Illustrate How the Company is Tackling Difficult-to-Treat Cancers
PR Newswire - Fri May 15, 2:25AM CDT
ASCO Abstract # Avelumab*: 3023, 3044, 3055, TPS9386, TPS3101, 4042, 4047, 5509, 8034; evofosfamide: TPS9089, 8579; tepotinib: 2591; tecemotide[+]: 3036.
Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody
Business Wire - Wed May 13, 4:01PM CDT
--First presentations at a major global medical meeting since the formation of the alliance between Merck KGaA, Darmstadt, Germany and Pfizer
PFE: 33.98 (-0.01)
Non-Tyrosine Kinase Inhibitors in Oncology, 2015 - 2025
M2 - Wed May 13, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6b765t/nontyrosine) has announced the addition of the "Non-Tyrosine Kinase Inhibitors in Oncology, 2015 - 2025" report to their offering. Apart from the bigger pharmaceutical companies such as Roche/Genentech, Eli Lilly, Novartis, Pfizer, AstraZeneca, several smaller/ start-up companies have shown their participation in this area. As the industry gains momentum, many companies have already benefitted by adopting the strategy of discovering the compounds and then out-licensing to bigger companies. The Non-Tyrosine Kinase Inhibitors in Oncology, 2015-2025 report provides a comprehensive analysis of the current market landscape and the future outlook of kinase inhibitors not specifically targeting tyrosine kinases. These include kinase inhibitors with activity against serine/threonine kinases, dual specificity kinases or both tyrosine and serine/threonine kinases being developed for oncological indications. Targeted therapy, specifically small molecule protein kinase inhibitors, has emerged as the new generation of cancer treatment that specifically targets only cancer cells. Although the market of protein kinase inhibitors is dominated by tyrosine kinase inhibitors, non-tyrosine kinase inhibitors (serine/threonine kinase inhibitors, dual specificity kinase inhibitors and drugs that inhibit both tyrosine and serine/threonine kinases) have gained a significant momentum in the last few years. There are total seven marketed non-tyrosine kinase inhibitors approved so far. Nexavar, the first drug of this type, received approval in 2005. Subsequently, Torisel (2007), Afinitor (2009), Zelboraf (2011), Tafinlar (2013), Mekinist (2013) and Ibrance (2015) were approved. The pipeline is rich and holds a significant potential for future. Most of the non-tyrosine kinase inhibitors identified during our research target mTOR, CDK, RAF and MEK kinases. In addition, there are several novel non-tyrosine kinase inhibitors under development that target other serine/threonine and dual specificity kinases (e.g. PLK1, ERK, PIM, Chk kinases). Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Targeted Cancer Therapy 4. Non-Tyrosine Kinase Inhibitors: Current Market Landscape 5. mTOR Inhibitors: Key Molecules and Future Outlook 6. Cdk Inhibitors: Key Molecules and Future Outlook 7. RAF / MEK Inhibitors: Key Molecules and Future Outlook 8. Novel Non-Tyrosine Kinase Inhibitors: Key Molecules and Future Outlook 9. Company Profiles 10. Interview Transcripts 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Profiles - Roche - Eli Lilly - Novartis - Array BioPharma - Nerviano Medical Sciences - Cyclacel Pharmaceuticals - Daiichi Sankyo - Onconova Therapeutics - AstraZeneca - GlaxoSmithKline (GSK) - Pfizer - Merck KGaA - Astex Pharmaceuticals - Carna Biosciences - Celgene Corporation - Non-Tyrosine Kinase Inhibitors Pipeline - Eternity Bioscience For more information visit http://www.researchandmarkets.com/research/6b...ontyrosine
CYCC: 0.77 (-0.04), ONTX: 2.81 (+0.09), LLY: 72.94 (+0.04), GSK: 44.66 (-0.11), NVS: 104.06 (+0.31), CELGZ: 2.60 (unch)
AOL and Rackspace are big market movers
AP - Tue May 12, 4:04PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
NBL: 45.11 (+0.23), MNST: 131.26 (-1.06), ACT: 295.76 (-0.84), RAX: 43.77 (-0.60), ESI: 2.51 (-0.29), DEPO: 20.22 (-0.32), DISH: 68.08 (+0.08), AOL: 50.55 (-0.09), THLD: 4.09 (+0.15), DF: 18.92 (+0.09), GPS: 39.25 (+0.36), VZ: 49.60 (-0.19), ZU: 13.48 (-0.03), PTIE: 2.08 (-0.12)
Threshold Pharma's evofosfamide Fast Track'd for pancreatic cancer; shares rise
Seeking Alpha - at Seeking Alpha - Tue May 12, 6:53AM CDT
THLD: 4.09 (+0.15)
Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer
PR Newswire - Tue May 12, 5:25AM CDT
-- Evofosfamide is an investigational compound currently in Phase III trials
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer
Marketwired - Tue May 12, 5:01AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's partner Merck KGaA, Darmstadt, Germany, for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. This is the second Fast Track designation for evofosfamide, the first having been granted to Threshold in November 2014 for the development of evofosfamide in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma. Threshold and Merck KGaA, Darmstadt, Germany, are collaborating on the development of evofosfamide, an investigational compound currently in Phase 3 clinical trials.
THLD: 4.09 (+0.15)
Aeterna Zentaris and EMD Serono Finalize Promotional Services Agreement for Saizen® (Somatropin (rDNA origin) for Injection) in the U.S.
CNW Group - Thu May 07, 6:30AM CDT
Aeterna Zentaris and Ascend Therapeutics(®) to join forces in selling EMD Serono's growth hormone deficiency therapy product
AEZ.TO: 0.52 (-0.01), AEZS: 0.42 (-0.01)
EMD Serono Initiates Co-Promotion of XALKORI® (crizotinib) with Pfizer in the United States
PR Newswire - Wed May 06, 7:00AM CDT
EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced it has begun co-promoting Pfizer's anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib) as part of its global strategic alliance with Pfizer. The initiation of field-based commercialization efforts for XALKORI illustrates the company's dedication to oncology, and to bringing important treatment options for challenging cancers to patients.
Major Big Biotech Deals and Alliances of 2014
M2 - Thu Apr 30, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2r4fv/big_biotech_deals) has announced the addition of the "Big Biotech Deals and Alliances of 2014" report to their offering. A review of big biotech partnering trends and comprehensive directory of deals and alliances announced during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2014's dealmaking and business activities. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2014. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2014. Key Topics Covered: Chapter 1 - Trends in dealmaking during 2014 1.1. Big biotech dealmaking activity 1.2. Partnering by deal type 1.3. Partnering by industry sector 1.4. Partnering by stage of development 1.5. Partnering by technology type 1.6. Partnering by therapy area Chapter 2 - Leading deals during 2014 2.1. Introduction 2.2. Top deals by value during 2012 Chapter 3 - Big biotech deals during 2014 3.1. Introduction 3.2. How to use big biotech partnering deals 3.3. Big biotech partnering company profiles for 2014 - Roche - Teva Pharmaceuticals - Amgen - Novo Nordisk - Merck KGaA - Gilead Sciences - Actavis - Biogen Idec - Celgene - Allergan - Valeant Pharmaceuticals - CSL - Shire - UCB - Grifols - Endo International - Sun Pharmaceutical - Regeneron Pharmaceuticals - Actelion - Ipsen - Alexion Pharmaceuticals - Vertex Pharmaceuticals - United Therapeutics - Cubist Pharmaceuticals - Salix Pharmaceuticals - Jazz Pharmaceuticals - Questcor Pharmaceuticals - The Medicines Company - LFB Group - Alkermes Chapter 4 - Partnering deals directory 2014 4.1. Introduction 4.2. Company A-Z 4.3. By deal type 4.4. By stage of development 4.5. By technology type 4.6. By therapy area For more information visit http://www.researchandmarkets.com/research/v2...tech_deals
BIIB: 395.42 (+4.18), VRTX: 127.31 (+1.10), CBSTZ: 0.06 (unch), UTHR: 179.30 (+6.55), SLXP: 172.96 (+0.15), AMGN: 163.44 (+1.08), ALKS: 60.47 (+0.47), AGN: 240.22 (+2.88), NVO: 56.92 (+0.17), GILD: 111.00 (+1.70), JAZZ: 180.06 (+2.05), ALXN: 163.16 (+2.60), REGN: 496.74 (+7.73), CELGZ: 2.60 (unch)
Big Pharma Deals and Alliances of 2014
M2 - Wed Apr 29, 10:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/skphqz/big_pharma_deals) has announced the addition of the "Big pharma Deals and Alliances of 2014" report to their offering. The Big Pharma Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2014's dealmaking and business activities. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report series also includes numerous tables and figures that illustrate the trends and activities in big pharma partnering and dealmaking during 2014. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2014. Key Topics Covered: Chapter 1 - Trends in dealmaking during 2014 1.1. Big pharma dealmaking activity 1.2. Partnering by deal type 1.3. Partnering by industry sector 1.4. Partnering by stage of development 1.5. Partnering by technology type 1.6. Partnering by therapy area Chapter 2 - Leading deals during 2014 2.1. Introduction 2.2. Top deals by value during 2014 Chapter 3 - Big pharma deals during 2014 3.1. Introduction 3.2. How to use big pharma partnering deals 3.3. Big pharma partnering company profiles for 2014 - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Valeant - Warner Chilcott - Watson Chapter 4 - Partnering deals directory 2014 4.1. Introduction 4.2. Company A-Z 4.3. By deal type 4.4. By stage of development 4.5. By technology type 4.6. By therapy area For more information visit http://www.researchandmarkets.com/research/sk...arma_deals
ENDP: 80.77 (-4.58), AMGN: 163.44 (+1.08), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), AGN: 240.22 (+2.88), NVO: 56.92 (+0.17), GILD: 111.00 (+1.70), BAX: 68.25 (-1.11), MRK: 60.01 (-0.22), NVS: 104.06 (+0.31), CELGZ: 2.60 (unch)
$350+ Million Fluorosurfactants Market Industry Trends & Forecasts to 2019
M2 - Wed Apr 29, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p8pxg3/fluorosurfactants) has announced the addition of the "Fluorosurfactants Market by Type (Amphoteric, Nonioninc, Anionic and Cationic), by Application (Paints & Coatings, Waxes, Polishes, Cleaners, Films, Adhesives and Others) & Region - Global Industry Trends & Forecasts to 2019" report to their offering. The fluorosurfactants market size in terms of value is projected to grow at a CAGR of 5.1% between 2014 and 2019 to reach $364.1 million by 2019 The fluorosurfactants have applications in paints & coatings, waxes, polishes, cleaners, films, adhesives and others. The fluorosurfactants market is expected to grow at a healthy growth rate in next five years driven by the increasing demand of paint & coatings and growing end user industries such as architecture, consumer goods and automotive. The market is segmented into four main types namely, amphoteric, nonionic, anionic and cationic. Growing advancements and technological inventions in fluorosurfactants industry would be quite effective in future. Fluorosurfactants have been well perceived in various dominant end-user markets in the last few decades and the consumption is expected to increase in emerging applications in the near future. Globally, North America dominated the fluorosurfactants market in 2013 whereas Asia-Pacific is projected to register highest CAGR in the forecast period. U.S., Germany, China, India, Mexico, Japan, and are the major countries with a huge demand for fluorosurfactants. Market players concentrated on launching environment friendly products, and expand their geographical reach. Other development strategies adopted by market players are agreements & collaborations, and mergers & acquisitions. The fluorosurfactants market is contemplating on executing high research activities to develop new environment friendly products. Negative impact of fluorosurfactants on environment is one of the major challenges for the market. The report analyzes the market on the basis of types, penetration of each application in each major region and country. It also covers the market behavior of leading producers, key developments, and strategies implemented to sustain and succeed in the market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Fluorosurfactants Market, By type 8 Fluorosurfactants Market, By Application 9 Fluorosurfactants Market, By Region 10 Competitive Landscape 11 Company Profiles - Advanced Polymer, Inc. (U.S.) - AGC Seimi Chemical Co., Ltd. (Japan) - ChemGuard (U.S.) - DIC Corporation (Japan) - DuPont (U.S.) - Dynax Corporation (U.S.) - Innovative Chemical Technologies, Inc. (U.S.) - Merck KGaA (Germany) - OMNOVA Solutions Inc. (U.S.) - The 3M Company (U.S.) For more information visit http://www.researchandmarkets.com/research/p8...urfactants
OMN: 7.70 (+0.08)
Top 50 Pharma Merger and Acquisition Deals and Alliances of 2014
M2 - Wed Apr 29, 6:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2t7tc/merger_and) has announced the addition of the "Merger and Acquisition Deals and Alliances of 2014" report to their offering. The Merger and Acquisition Deals of 2014 provides comprehensive understanding and unprecedented access to the M&A deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the M&A activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2014's M&A dealmaking and business activities. The chapter is organized by company A-Z. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma M&A dealmaking during 2014. In conclusion, this report provides everything a prospective M&A dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2014 Key Topics Covered: Chapter 1 - Trends in M&A dealmaking during 2014 1.1. Dealmaking activity by month 1.2. M&A by therapy area 1.3. M&A by industry sector Chapter 2 - Leading M&A deals during 2014 2.1. Introduction 2.2. Top deals by value during 2014 2.3 Most active M&A dealmakers during 2014 Chapter 3 - Big pharma M&A deals during 2014 3.1. Introduction 3.2. How to use big pharma M&A deals 3.3. Big pharma M&A company profiles for 2014 - Abbott - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Takeda - Teva - Valeant - Warner Chilcott - Watson Chapter 4 - M&A deals directory 2014 4.1. Introduction 4.2. Company A-Z For more information visit http://www.researchandmarkets.com/research/s2t7tc/merger_and
ENDP: 80.77 (-4.58), NVO: 56.92 (+0.17), GILD: 111.00 (+1.70), BAX: 68.25 (-1.11), LLY: 72.94 (+0.04), GSK: 44.66 (-0.11), BMY: 68.00 (+0.36), NVS: 104.06 (+0.31), CELGZ: 2.60 (unch)
Neuropathy Partnering Deals and Agreements Analysis 2010-2015
M2 - Mon Apr 27, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf2xtc/neuropathy) has announced the addition of the "Neuropathy Partnering 2010-2015" report to their offering. The Neuropathy Partnering 2010-2015 provides understanding and access to the neuropathy partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of neuropathy partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors neuropathy technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 30 links to online copies of actual neuropathy deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in neuropathy dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 30 neuropathy deals and contract documents where available - The leading neuropathy deals by value since 2010 In Neuropathy Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned - Abbott - Abbvie - Actavis - Watson Pharmaceuticals - Allergan - Amgen - Astellas - Astellas Pharma US - AstraZeneca - Baxter International - Bayer - Chugai Pharma Marketing - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Janssen Research & Development - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Sanofi-Aventis - Sanofi-Pasteur - Servier - Shionogi - BioMarin Pharmaceuticals - Cangene - Cubist - Dendreon - Elan - Emergent BioSolutions - Galapagos - Genmab - Grifols For more information visit http://www.researchandmarkets.com/research/zf2xtc/neuropathy
AGN: 240.22 (+2.88), EBS: 30.91 (+0.19), BAX: 68.25 (-1.11), AMGN: 163.44 (+1.08)
Thrombus Partnering Deals and Agreements Analysis 2010-2015
M2 - Mon Apr 27, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2fhv9/thrombus) has announced the addition of the "Thrombus Partnering 2010-2015" report to their offering. The Thrombus Partnering 2010-2015 provides understanding and access to the thrombus partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of thrombus partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors thrombus technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 35 links to online copies of actual thrombus deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in thrombus dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 35 thrombus deals and contract documents where available - The leading thrombus deals by value since 2010 In Thrombus Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned: - Abbott - Abbvie - Actavis - Watson Pharmaceuticals - Allergan - Amgen - Astellas - Astellas Pharma US - AstraZeneca - Baxter International - Bayer - Chugai Pharma Marketing - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Janssen Research & Development - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Sanofi-Aventis - Sanofi-Pasteur - Servier - Shionogi - BioMarin Pharmaceuticals - Cangene - Cubist - Dendreon - Elan - Emergent BioSolutions - Galapagos - Genmab - Grifols For more information visit http://www.researchandmarkets.com/research/s2fhv9/thrombus
AGN: 240.22 (+2.88), EBS: 30.91 (+0.19), BAX: 68.25 (-1.11), AMGN: 163.44 (+1.08)
Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2015
M2 - Mon Apr 27, 8:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/334b6p/clinical_stage) has announced the addition of the "Clinical Stage Partnering Terms and Agreements in Pharma and Biotech" report to their offering. The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 2,000 links to online copies of actual clinical stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Why do companies partner clinical stage compounds? Chapter 3 - Clinical stage deal strategies and structure Chapter 4 - Clinical stage partnering payment strategies Chapter 5 - Trends in clinical stage deal making Chapter 6 - Average payment terms for clinical stage partnering Chapter 7 - Leading clinical stage deals Chapter 8 - Big pharma and big biotech clinical stage partnering deals Chapter 9 - Clinical stage partnering contracts directory Chapter 10 - Clinical stage dealmaking by development stage Companies Featured (Partial List) - Abbott - Abbvie - Actavis - Watson Pharmaceuticals - Allergan - Amgen - Astellas - Astellas Pharma US - AstraZeneca - Baxter International - Bayer - Chugai Pharma Marketing - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Janssen Research & Development - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Sanofi-Aventis - Sanofi-Pasteur - Servier - Shionogi - BioMarin Pharmaceuticals - Cangene - Cubist - Dendreon - Elan - Emergent BioSolutions - Galapagos - Genmab - Grifols For more information visit http://www.researchandmarkets.com/research/33...ical_stage
AGN: 240.22 (+2.88), EBS: 30.91 (+0.19), BAX: 68.25 (-1.11), AMGN: 163.44 (+1.08)
Hypercholesterolemia Partnering Deals and Agreements Analysis 2010-2015
M2 - Mon Apr 27, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lczhlb/hypercholesterolem) has announced the addition of the "Hypercholesterolemia Partnering 2010-2015" report to their offering. The Hypercholesterolemia Partnering 2010-2015 provides understanding and access to the hypercholesterolemia partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of hypercholesterolemia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors hypercholesterolemia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 50 links to online copies of actual hypercholesterolemia deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Report scope This data driven report includes: - Trends in hypercholesterolemia dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 50 hypercholesterolemia deals and contract documents where available - The leading hypercholesterolemia deals by value since 2010 In Hypercholesterolemia Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/lc...lesterolem
BIIB: 395.42 (+4.18), AMGN: 163.44 (+1.08), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), AGN: 240.22 (+2.88), JNJ: 103.42 (+1.12), NVO: 56.92 (+0.17), GILD: 111.00 (+1.70), BAX: 68.25 (-1.11), MRK: 60.01 (-0.22), NVS: 104.06 (+0.31)
Merck KGaA, Darmstadt, Germany to Present Data at ASCO That Illustrate How the Company is Tackling Difficult-to-Treat Cancers
PR Newswire - Fri May 15, 2:25AM CDT
ASCO Abstract # Avelumab*: 3023, 3044, 3055, TPS9386, TPS3101, 4042, 4047, 5509, 8034; evofosfamide: TPS9089, 8579; tepotinib: 2591; tecemotide[+]: 3036.
Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody
Business Wire - Wed May 13, 4:01PM CDT
--First presentations at a major global medical meeting since the formation of the alliance between Merck KGaA, Darmstadt, Germany and Pfizer
PFE: 33.98 (-0.01)
Non-Tyrosine Kinase Inhibitors in Oncology, 2015 - 2025
M2 - Wed May 13, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6b765t/nontyrosine) has announced the addition of the "Non-Tyrosine Kinase Inhibitors in Oncology, 2015 - 2025" report to their offering. Apart from the bigger pharmaceutical companies such as Roche/Genentech, Eli Lilly, Novartis, Pfizer, AstraZeneca, several smaller/ start-up companies have shown their participation in this area. As the industry gains momentum, many companies have already benefitted by adopting the strategy of discovering the compounds and then out-licensing to bigger companies. The Non-Tyrosine Kinase Inhibitors in Oncology, 2015-2025 report provides a comprehensive analysis of the current market landscape and the future outlook of kinase inhibitors not specifically targeting tyrosine kinases. These include kinase inhibitors with activity against serine/threonine kinases, dual specificity kinases or both tyrosine and serine/threonine kinases being developed for oncological indications. Targeted therapy, specifically small molecule protein kinase inhibitors, has emerged as the new generation of cancer treatment that specifically targets only cancer cells. Although the market of protein kinase inhibitors is dominated by tyrosine kinase inhibitors, non-tyrosine kinase inhibitors (serine/threonine kinase inhibitors, dual specificity kinase inhibitors and drugs that inhibit both tyrosine and serine/threonine kinases) have gained a significant momentum in the last few years. There are total seven marketed non-tyrosine kinase inhibitors approved so far. Nexavar, the first drug of this type, received approval in 2005. Subsequently, Torisel (2007), Afinitor (2009), Zelboraf (2011), Tafinlar (2013), Mekinist (2013) and Ibrance (2015) were approved. The pipeline is rich and holds a significant potential for future. Most of the non-tyrosine kinase inhibitors identified during our research target mTOR, CDK, RAF and MEK kinases. In addition, there are several novel non-tyrosine kinase inhibitors under development that target other serine/threonine and dual specificity kinases (e.g. PLK1, ERK, PIM, Chk kinases). Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Targeted Cancer Therapy 4. Non-Tyrosine Kinase Inhibitors: Current Market Landscape 5. mTOR Inhibitors: Key Molecules and Future Outlook 6. Cdk Inhibitors: Key Molecules and Future Outlook 7. RAF / MEK Inhibitors: Key Molecules and Future Outlook 8. Novel Non-Tyrosine Kinase Inhibitors: Key Molecules and Future Outlook 9. Company Profiles 10. Interview Transcripts 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Profiles - Roche - Eli Lilly - Novartis - Array BioPharma - Nerviano Medical Sciences - Cyclacel Pharmaceuticals - Daiichi Sankyo - Onconova Therapeutics - AstraZeneca - GlaxoSmithKline (GSK) - Pfizer - Merck KGaA - Astex Pharmaceuticals - Carna Biosciences - Celgene Corporation - Non-Tyrosine Kinase Inhibitors Pipeline - Eternity Bioscience For more information visit http://www.researchandmarkets.com/research/6b...ontyrosine
CYCC: 0.77 (-0.04), ONTX: 2.81 (+0.09), LLY: 72.94 (+0.04), GSK: 44.66 (-0.11), NVS: 104.06 (+0.31), CELGZ: 2.60 (unch)
AOL and Rackspace are big market movers
AP - Tue May 12, 4:04PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
NBL: 45.11 (+0.23), MNST: 131.26 (-1.06), ACT: 295.76 (-0.84), RAX: 43.77 (-0.60), ESI: 2.51 (-0.29), DEPO: 20.22 (-0.32), DISH: 68.08 (+0.08), AOL: 50.55 (-0.09), THLD: 4.09 (+0.15), DF: 18.92 (+0.09), GPS: 39.25 (+0.36), VZ: 49.60 (-0.19), ZU: 13.48 (-0.03), PTIE: 2.08 (-0.12)
Threshold Pharma's evofosfamide Fast Track'd for pancreatic cancer; shares rise
Seeking Alpha - at Seeking Alpha - Tue May 12, 6:53AM CDT
THLD: 4.09 (+0.15)
Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer
PR Newswire - Tue May 12, 5:25AM CDT
-- Evofosfamide is an investigational compound currently in Phase III trials
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer
Marketwired - Tue May 12, 5:01AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's partner Merck KGaA, Darmstadt, Germany, for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. This is the second Fast Track designation for evofosfamide, the first having been granted to Threshold in November 2014 for the development of evofosfamide in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma. Threshold and Merck KGaA, Darmstadt, Germany, are collaborating on the development of evofosfamide, an investigational compound currently in Phase 3 clinical trials.
THLD: 4.09 (+0.15)
Aeterna Zentaris and EMD Serono Finalize Promotional Services Agreement for Saizen® (Somatropin (rDNA origin) for Injection) in the U.S.
CNW Group - Thu May 07, 6:30AM CDT
Aeterna Zentaris and Ascend Therapeutics(®) to join forces in selling EMD Serono's growth hormone deficiency therapy product
AEZ.TO: 0.52 (-0.01), AEZS: 0.42 (-0.01)
EMD Serono Initiates Co-Promotion of XALKORI® (crizotinib) with Pfizer in the United States
PR Newswire - Wed May 06, 7:00AM CDT
EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced it has begun co-promoting Pfizer's anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib) as part of its global strategic alliance with Pfizer. The initiation of field-based commercialization efforts for XALKORI illustrates the company's dedication to oncology, and to bringing important treatment options for challenging cancers to patients.
Major Big Biotech Deals and Alliances of 2014
M2 - Thu Apr 30, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2r4fv/big_biotech_deals) has announced the addition of the "Big Biotech Deals and Alliances of 2014" report to their offering. A review of big biotech partnering trends and comprehensive directory of deals and alliances announced during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2014's dealmaking and business activities. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2014. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2014. Key Topics Covered: Chapter 1 - Trends in dealmaking during 2014 1.1. Big biotech dealmaking activity 1.2. Partnering by deal type 1.3. Partnering by industry sector 1.4. Partnering by stage of development 1.5. Partnering by technology type 1.6. Partnering by therapy area Chapter 2 - Leading deals during 2014 2.1. Introduction 2.2. Top deals by value during 2012 Chapter 3 - Big biotech deals during 2014 3.1. Introduction 3.2. How to use big biotech partnering deals 3.3. Big biotech partnering company profiles for 2014 - Roche - Teva Pharmaceuticals - Amgen - Novo Nordisk - Merck KGaA - Gilead Sciences - Actavis - Biogen Idec - Celgene - Allergan - Valeant Pharmaceuticals - CSL - Shire - UCB - Grifols - Endo International - Sun Pharmaceutical - Regeneron Pharmaceuticals - Actelion - Ipsen - Alexion Pharmaceuticals - Vertex Pharmaceuticals - United Therapeutics - Cubist Pharmaceuticals - Salix Pharmaceuticals - Jazz Pharmaceuticals - Questcor Pharmaceuticals - The Medicines Company - LFB Group - Alkermes Chapter 4 - Partnering deals directory 2014 4.1. Introduction 4.2. Company A-Z 4.3. By deal type 4.4. By stage of development 4.5. By technology type 4.6. By therapy area For more information visit http://www.researchandmarkets.com/research/v2...tech_deals
BIIB: 395.42 (+4.18), VRTX: 127.31 (+1.10), CBSTZ: 0.06 (unch), UTHR: 179.30 (+6.55), SLXP: 172.96 (+0.15), AMGN: 163.44 (+1.08), ALKS: 60.47 (+0.47), AGN: 240.22 (+2.88), NVO: 56.92 (+0.17), GILD: 111.00 (+1.70), JAZZ: 180.06 (+2.05), ALXN: 163.16 (+2.60), REGN: 496.74 (+7.73), CELGZ: 2.60 (unch)
Big Pharma Deals and Alliances of 2014
M2 - Wed Apr 29, 10:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/skphqz/big_pharma_deals) has announced the addition of the "Big pharma Deals and Alliances of 2014" report to their offering. The Big Pharma Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2014's dealmaking and business activities. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report series also includes numerous tables and figures that illustrate the trends and activities in big pharma partnering and dealmaking during 2014. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2014. Key Topics Covered: Chapter 1 - Trends in dealmaking during 2014 1.1. Big pharma dealmaking activity 1.2. Partnering by deal type 1.3. Partnering by industry sector 1.4. Partnering by stage of development 1.5. Partnering by technology type 1.6. Partnering by therapy area Chapter 2 - Leading deals during 2014 2.1. Introduction 2.2. Top deals by value during 2014 Chapter 3 - Big pharma deals during 2014 3.1. Introduction 3.2. How to use big pharma partnering deals 3.3. Big pharma partnering company profiles for 2014 - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Valeant - Warner Chilcott - Watson Chapter 4 - Partnering deals directory 2014 4.1. Introduction 4.2. Company A-Z 4.3. By deal type 4.4. By stage of development 4.5. By technology type 4.6. By therapy area For more information visit http://www.researchandmarkets.com/research/sk...arma_deals
ENDP: 80.77 (-4.58), AMGN: 163.44 (+1.08), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), AGN: 240.22 (+2.88), NVO: 56.92 (+0.17), GILD: 111.00 (+1.70), BAX: 68.25 (-1.11), MRK: 60.01 (-0.22), NVS: 104.06 (+0.31), CELGZ: 2.60 (unch)
$350+ Million Fluorosurfactants Market Industry Trends & Forecasts to 2019
M2 - Wed Apr 29, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p8pxg3/fluorosurfactants) has announced the addition of the "Fluorosurfactants Market by Type (Amphoteric, Nonioninc, Anionic and Cationic), by Application (Paints & Coatings, Waxes, Polishes, Cleaners, Films, Adhesives and Others) & Region - Global Industry Trends & Forecasts to 2019" report to their offering. The fluorosurfactants market size in terms of value is projected to grow at a CAGR of 5.1% between 2014 and 2019 to reach $364.1 million by 2019 The fluorosurfactants have applications in paints & coatings, waxes, polishes, cleaners, films, adhesives and others. The fluorosurfactants market is expected to grow at a healthy growth rate in next five years driven by the increasing demand of paint & coatings and growing end user industries such as architecture, consumer goods and automotive. The market is segmented into four main types namely, amphoteric, nonionic, anionic and cationic. Growing advancements and technological inventions in fluorosurfactants industry would be quite effective in future. Fluorosurfactants have been well perceived in various dominant end-user markets in the last few decades and the consumption is expected to increase in emerging applications in the near future. Globally, North America dominated the fluorosurfactants market in 2013 whereas Asia-Pacific is projected to register highest CAGR in the forecast period. U.S., Germany, China, India, Mexico, Japan, and are the major countries with a huge demand for fluorosurfactants. Market players concentrated on launching environment friendly products, and expand their geographical reach. Other development strategies adopted by market players are agreements & collaborations, and mergers & acquisitions. The fluorosurfactants market is contemplating on executing high research activities to develop new environment friendly products. Negative impact of fluorosurfactants on environment is one of the major challenges for the market. The report analyzes the market on the basis of types, penetration of each application in each major region and country. It also covers the market behavior of leading producers, key developments, and strategies implemented to sustain and succeed in the market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Fluorosurfactants Market, By type 8 Fluorosurfactants Market, By Application 9 Fluorosurfactants Market, By Region 10 Competitive Landscape 11 Company Profiles - Advanced Polymer, Inc. (U.S.) - AGC Seimi Chemical Co., Ltd. (Japan) - ChemGuard (U.S.) - DIC Corporation (Japan) - DuPont (U.S.) - Dynax Corporation (U.S.) - Innovative Chemical Technologies, Inc. (U.S.) - Merck KGaA (Germany) - OMNOVA Solutions Inc. (U.S.) - The 3M Company (U.S.) For more information visit http://www.researchandmarkets.com/research/p8...urfactants
OMN: 7.70 (+0.08)
Top 50 Pharma Merger and Acquisition Deals and Alliances of 2014
M2 - Wed Apr 29, 6:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2t7tc/merger_and) has announced the addition of the "Merger and Acquisition Deals and Alliances of 2014" report to their offering. The Merger and Acquisition Deals of 2014 provides comprehensive understanding and unprecedented access to the M&A deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the M&A activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2014's M&A dealmaking and business activities. The chapter is organized by company A-Z. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma M&A dealmaking during 2014. In conclusion, this report provides everything a prospective M&A dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2014 Key Topics Covered: Chapter 1 - Trends in M&A dealmaking during 2014 1.1. Dealmaking activity by month 1.2. M&A by therapy area 1.3. M&A by industry sector Chapter 2 - Leading M&A deals during 2014 2.1. Introduction 2.2. Top deals by value during 2014 2.3 Most active M&A dealmakers during 2014 Chapter 3 - Big pharma M&A deals during 2014 3.1. Introduction 3.2. How to use big pharma M&A deals 3.3. Big pharma M&A company profiles for 2014 - Abbott - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Takeda - Teva - Valeant - Warner Chilcott - Watson Chapter 4 - M&A deals directory 2014 4.1. Introduction 4.2. Company A-Z For more information visit http://www.researchandmarkets.com/research/s2t7tc/merger_and
ENDP: 80.77 (-4.58), NVO: 56.92 (+0.17), GILD: 111.00 (+1.70), BAX: 68.25 (-1.11), LLY: 72.94 (+0.04), GSK: 44.66 (-0.11), BMY: 68.00 (+0.36), NVS: 104.06 (+0.31), CELGZ: 2.60 (unch)
Neuropathy Partnering Deals and Agreements Analysis 2010-2015
M2 - Mon Apr 27, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf2xtc/neuropathy) has announced the addition of the "Neuropathy Partnering 2010-2015" report to their offering. The Neuropathy Partnering 2010-2015 provides understanding and access to the neuropathy partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of neuropathy partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors neuropathy technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 30 links to online copies of actual neuropathy deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in neuropathy dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 30 neuropathy deals and contract documents where available - The leading neuropathy deals by value since 2010 In Neuropathy Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned - Abbott - Abbvie - Actavis - Watson Pharmaceuticals - Allergan - Amgen - Astellas - Astellas Pharma US - AstraZeneca - Baxter International - Bayer - Chugai Pharma Marketing - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Janssen Research & Development - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Sanofi-Aventis - Sanofi-Pasteur - Servier - Shionogi - BioMarin Pharmaceuticals - Cangene - Cubist - Dendreon - Elan - Emergent BioSolutions - Galapagos - Genmab - Grifols For more information visit http://www.researchandmarkets.com/research/zf2xtc/neuropathy
AGN: 240.22 (+2.88), EBS: 30.91 (+0.19), BAX: 68.25 (-1.11), AMGN: 163.44 (+1.08)
Thrombus Partnering Deals and Agreements Analysis 2010-2015
M2 - Mon Apr 27, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2fhv9/thrombus) has announced the addition of the "Thrombus Partnering 2010-2015" report to their offering. The Thrombus Partnering 2010-2015 provides understanding and access to the thrombus partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of thrombus partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors thrombus technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 35 links to online copies of actual thrombus deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in thrombus dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 35 thrombus deals and contract documents where available - The leading thrombus deals by value since 2010 In Thrombus Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned: - Abbott - Abbvie - Actavis - Watson Pharmaceuticals - Allergan - Amgen - Astellas - Astellas Pharma US - AstraZeneca - Baxter International - Bayer - Chugai Pharma Marketing - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Janssen Research & Development - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Sanofi-Aventis - Sanofi-Pasteur - Servier - Shionogi - BioMarin Pharmaceuticals - Cangene - Cubist - Dendreon - Elan - Emergent BioSolutions - Galapagos - Genmab - Grifols For more information visit http://www.researchandmarkets.com/research/s2fhv9/thrombus
AGN: 240.22 (+2.88), EBS: 30.91 (+0.19), BAX: 68.25 (-1.11), AMGN: 163.44 (+1.08)
Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2015
M2 - Mon Apr 27, 8:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/334b6p/clinical_stage) has announced the addition of the "Clinical Stage Partnering Terms and Agreements in Pharma and Biotech" report to their offering. The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 2,000 links to online copies of actual clinical stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Why do companies partner clinical stage compounds? Chapter 3 - Clinical stage deal strategies and structure Chapter 4 - Clinical stage partnering payment strategies Chapter 5 - Trends in clinical stage deal making Chapter 6 - Average payment terms for clinical stage partnering Chapter 7 - Leading clinical stage deals Chapter 8 - Big pharma and big biotech clinical stage partnering deals Chapter 9 - Clinical stage partnering contracts directory Chapter 10 - Clinical stage dealmaking by development stage Companies Featured (Partial List) - Abbott - Abbvie - Actavis - Watson Pharmaceuticals - Allergan - Amgen - Astellas - Astellas Pharma US - AstraZeneca - Baxter International - Bayer - Chugai Pharma Marketing - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Janssen Research & Development - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Sanofi-Aventis - Sanofi-Pasteur - Servier - Shionogi - BioMarin Pharmaceuticals - Cangene - Cubist - Dendreon - Elan - Emergent BioSolutions - Galapagos - Genmab - Grifols For more information visit http://www.researchandmarkets.com/research/33...ical_stage
AGN: 240.22 (+2.88), EBS: 30.91 (+0.19), BAX: 68.25 (-1.11), AMGN: 163.44 (+1.08)
Hypercholesterolemia Partnering Deals and Agreements Analysis 2010-2015
M2 - Mon Apr 27, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lczhlb/hypercholesterolem) has announced the addition of the "Hypercholesterolemia Partnering 2010-2015" report to their offering. The Hypercholesterolemia Partnering 2010-2015 provides understanding and access to the hypercholesterolemia partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of hypercholesterolemia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors hypercholesterolemia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 50 links to online copies of actual hypercholesterolemia deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Report scope This data driven report includes: - Trends in hypercholesterolemia dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 50 hypercholesterolemia deals and contract documents where available - The leading hypercholesterolemia deals by value since 2010 In Hypercholesterolemia Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/lc...lesterolem
BIIB: 395.42 (+4.18), AMGN: 163.44 (+1.08), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), AGN: 240.22 (+2.88), JNJ: 103.42 (+1.12), NVO: 56.92 (+0.17), GILD: 111.00 (+1.70), BAX: 68.25 (-1.11), MRK: 60.01 (-0.22), NVS: 104.06 (+0.31)
